139 related articles for article (PubMed ID: 34725358)
1. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.
Paparella AS; Aboulache BL; Harijan RK; Potts KS; Tyler PC; Schramm VL
Nat Commun; 2021 Nov; 12(1):6285. PubMed ID: 34725358
[TBL] [Abstract][Full Text] [Related]
2. Isofagomine inhibits multiple TcdB variants and protects mice from
Paparella AS; Brew I; Hong HA; Ferriera W; Cutting S; Lamiable-Oulaidi F; Popadynec M; Tyler PC; Schramm VL
bioRxiv; 2023 Sep; ():. PubMed ID: 37781587
[No Abstract] [Full Text] [Related]
3. The Importance of Therapeutically Targeting the Binary Toxin from
Abeyawardhane DL; Godoy-Ruiz R; Adipietro KA; Varney KM; Rustandi RR; Pozharski E; Weber DJ
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805767
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the Endosomal Anion/Proton Exchanger ClC-5 Increases Cell Susceptibility toward
Ruhe F; Olling A; Abromeit R; Rataj D; Grieschat M; Zeug A; Gerhard R; Alekov A
Front Cell Infect Microbiol; 2017; 7():67. PubMed ID: 28348980
[TBL] [Abstract][Full Text] [Related]
5. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
6. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
Kordus SL; Kroh HK; Rodríguez RC; Shrem RA; Peritore-Galve FC; Shupe JA; Wadzinski BE; Lacy DB; Spiller BW
PLoS Pathog; 2023 Oct; 19(10):e1011496. PubMed ID: 37871122
[TBL] [Abstract][Full Text] [Related]
7. A leaky human colon model reveals uncoupled apical/basal cytotoxicity in early
Ok MT; Liu J; Bliton RJ; Hinesley CM; San Pedro EET; Breau KA; Gomez-Martinez I; Burclaff J; Magness ST
Am J Physiol Gastrointest Liver Physiol; 2023 Apr; 324(4):G262-G280. PubMed ID: 36749911
[No Abstract] [Full Text] [Related]
8. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
Aminzadeh A; Hilgers L; Paul Platenburg P; Riou M; Perrot N; Rossignol C; Cauty A; Barc C; Jørgensen R
Vaccine; 2024 Mar; 42(7):1582-1592. PubMed ID: 38336558
[TBL] [Abstract][Full Text] [Related]
9. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
[TBL] [Abstract][Full Text] [Related]
10. Structure of the glucosyltransferase domain of TcdA in complex with RhoA provides insights into substrate recognition.
Chen B; Liu Z; Perry K; Jin R
Sci Rep; 2022 May; 12(1):9028. PubMed ID: 35637242
[TBL] [Abstract][Full Text] [Related]
11. A Streamlined Method to Obtain Biologically Active TcdA and TcdB Toxins from
Sapa D; Brosse A; Coullon H; Péan de Ponfilly G; Candela T; Le Monnier A
Toxins (Basel); 2024 Jan; 16(1):. PubMed ID: 38251254
[TBL] [Abstract][Full Text] [Related]
12. Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
Peng Z; Simeon R; Mitchell SB; Zhang J; Feng H; Chen Z
mSphere; 2019 Oct; 4(5):. PubMed ID: 31578248
[No Abstract] [Full Text] [Related]
13. A human gut ecosystem protects against C. difficile disease by targeting TcdA.
Martz SL; Guzman-Rodriguez M; He SM; Noordhof C; Hurlbut DJ; Gloor GB; Carlucci C; Weese S; Allen-Vercoe E; Sun J; Claud EC; Petrof EO
J Gastroenterol; 2017 Apr; 52(4):452-465. PubMed ID: 27329502
[TBL] [Abstract][Full Text] [Related]
14. Increased intestinal permeability and downregulation of absorptive ion transporters
Peritore-Galve FC; Kaji I; Smith A; Walker LM; Shupe JA; Washington MK; Algood HMS; Dudeja PK; Goldenring JR; Lacy DB
Gut Microbes; 2023; 15(1):2225841. PubMed ID: 37350393
[TBL] [Abstract][Full Text] [Related]
15. Enteric glial cells are susceptible to Clostridium difficile toxin B.
Fettucciari K; Ponsini P; Gioè D; Macchioni L; Palumbo C; Antonelli E; Coaccioli S; Villanacci V; Corazzi L; Marconi P; Bassotti G
Cell Mol Life Sci; 2017 Apr; 74(8):1527-1551. PubMed ID: 27891552
[TBL] [Abstract][Full Text] [Related]
16.
Xiao X; Sarma S; Menegatti S; Crook N; Magness ST; Hall CK
ACS Chem Biol; 2022 Jan; 17(1):118-128. PubMed ID: 34965093
[No Abstract] [Full Text] [Related]
17. Pro-Inflammatory Cytokines Enhanced In Vitro Cytotoxic Activity of
Fettucciari K; Spaterna A; Marconi P; Bassotti G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256032
[TBL] [Abstract][Full Text] [Related]
18. Protective Effects of Alginate and Chitosan Oligosaccharides against
Mavrogeni ME; Asadpoor M; Judernatz JH; van Ark I; Wösten MMSM; Strijbis K; Pieters RJ; Folkerts G; Braber S
Toxins (Basel); 2023 Sep; 15(10):. PubMed ID: 37888617
[No Abstract] [Full Text] [Related]
19. Crystal structure of Clostridium difficile toxin A.
Chumbler NM; Rutherford SA; Zhang Z; Farrow MA; Lisher JP; Farquhar E; Giedroc DP; Spiller BW; Melnyk RA; Lacy DB
Nat Microbiol; 2016 Jan; 1():15002. PubMed ID: 27571750
[TBL] [Abstract][Full Text] [Related]
20. Conformational analysis of Clostridium difficile toxin B and its implications for substrate recognition.
Swett R; Cisneros GA; Feig AL
PLoS One; 2012; 7(7):e41518. PubMed ID: 22844485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
